

Adult CIRB - Late Phase Emphasis Meeting Agenda

June 17, 2021

I Amendment Prior to Activation

A051902, A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas (Protocol Version Date 05/28/21)

II Continuing Review

A011801, The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSEssment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib (Protocol Version Date 12/01/20)

III Continuing Review

EA6191, The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAFV600E/K Melanoma with elevated LDH (Protocol Version Date 01/27/21)

IV Continuing Review

NRG-GY022, Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin (Protocol Version Date 01/20/21)

V Continuing Review

S1922, Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI In Refractory Small Bowel Adenocarcinoma (Protocol Version Date 08/20/20)



FOR THE NATIONAL CANCER INSTITUTE

VI New Study - Initial Review

A082002, A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer (Protocol Version Date 05/19/21)

VII New Study - Initial Review

AMC-S005, Biospecimen Collection and Donation to the AIDS and Cancer Specimen Resource (ACSR): A Companion Protocol to AMC Trials (Protocol Version Date 05/10/21)
